Alternative promoter use is not uncommon in human genes, but activation of the MYB gene in ACC tumors is thought to occur through chromosomal translocations that lead to ‘enhancer hijacking’ when distant enhancers are brought to the vicinity of the MYB gene, allowing its aberrant expression in ACC tumor cells [11]. This evidence concerns the gene MYB and adrenal cortex carcinoma.